- Home
- KNSL vs IBRX Comparison
KNSL vs IBRX Comparison
Compare KNSL & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KNSL | IBRX |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 7.5B |
| IPO Year | 2016 | 2015 |
Fundamental Metrics
Financial Performance| Metric | KNSL | IBRX |
|---|---|---|
| Price | $327.51 | $7.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 7 |
| Target Price | ★ $403.45 | $12.57 |
| AVG Volume (30 Days) | 237.3K | ★ 14.3M |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.31% | N/A |
| EPS Growth | 21.77 | ★ 38.71 |
| EPS | ★ 4.88 | N/A |
| Revenue | ★ $1,873,987,000.00 | $113,288,000.00 |
| Revenue This Year | $5.60 | $88.59 |
| Revenue Next Year | $7.88 | $131.15 |
| P/E Ratio | $70.35 | ★ N/A |
| Revenue Growth | 18.04 | ★ 668.31 |
| 52 Week Low | $321.97 | $1.83 |
| 52 Week High | $512.76 | $12.43 |
Technical Indicators
Market Signals| Indicator | KNSL | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 34.58 | 44.66 |
| Support Level | $321.97 | $2.22 |
| Resistance Level | $364.61 | $8.28 |
| Average True Range (ATR) | 11.64 | 0.57 |
| MACD | -1.18 | 0.01 |
| Stochastic Oscillator | 13.65 | 20.17 |
Price Performance
Historical ComparisonAbout KNSL Kinsale Capital Group Inc.
Kinsale Capital Group Inc is an insurance holding company. The company is engaged in offering property, casualty, and specialty insurance products. It offers specialty insurance products for allied health, healthcare, life sciences, professional, and a public entity. The company operates in only one reportable segment which is the Excess and Surplus Lines Insurance segment, which includes commercial excess and surplus lines liability and property insurance products through its underwriting divisions. The company generates revenues in the form of premiums and investment income.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.